Dr. Tak Mak is a Senior Scientist at the Ontario Cancer Institute, Princess Margaret Cancer Centre in Toronto. He is a Canadian medical researcher, geneticist, oncologist, and biochemist. He first became widely known for his discovery of the T-cell receptor in 1983 and pioneering work in the genetics of immunology. In 1995, Mak published a landmark paper on the discovery of the function of the immune checkpoint protein CTLA-4, thus opening the path for immunotherapy/checkpoint inhibitors as a means of cancer treatment. Mak is also the founder of Agios Pharmaceuticals, whose lead compound, IDHIFA®, was approved by the FDA for Acute myeloid leukemia in August 2017, becoming the first drug specifically targeting cancer metabolism to be used for cancer treatment. He has worked in a variety of areas including biochemistry, immunology, and cancer genetics.
At his keynote address during the 2018 Conference in Toronto, Ontario, this May, he will offer his insight on T-Cell mediated Immune Therapies (See video: Dr. Mak discusses presentation).
Dr. Mak joins an assembly of esteemed colleagues and thought leaders to discuss the frontier of immune-oncology treatments for patients with advanced cancers. The session will cover basic and clinical research evolving around gene therapies, gene editing, autologous T cell therapies (CAR T) and immune checkpoint inhibitors. The benefits and challenges of exploratory use of multiple combos of these treatments will also be presented and discussed.
The Canadian Society for Pharmaceutical Sciences (CSPS) 2018 Conference, being held May 22-25, 2018, is a joint conference with Canadian Society of Pharmacology and Therapeutics (CSPT) and Canadian Chapter of Controlled Release Society (CC-CRS).
Reserve your seat by April 10th to save $200 on your Symposium registration.